Literature DB >> 31020912

B Cell-Activating Factor Is Associated with Testosterone and Smoking Status in Non-Ambulatory Men with Chronic Spinal Cord Injury.

Ricardo A Battaglino1, Nguyen Nguyen1, Megan Summers2, Leslie R Morse1,2.   

Abstract

B cell-mediated autoimmunity may contribute to poor neurological outcomes after spinal cord injury (SCI). B cell-activating factor (BAFF) is a key cytokine involved in B cell development, proliferation, activation, and survival whose expression is elevated in men with chronic SCI. The aim of this study was to assess factors associated with circulating BAFF in non-ambulatory males with chronic SCI. We assessed the association between clinical and demographic factors, health habits, and circulating BAFF levels in a convenience sample of 43 non-ambulatory men with chronic spinal cord injury (≥ 1 year post-injury). Serum BAFF and total testosterone levels were quantified by enzyme-linked immunosorbent assay. Body composition was determined by whole body dual-energy X-ray absorptiometry. In multivariable models, active smokers had significantly greater BAFF levels than former/nonsmokers (871 pg/mL vs. 665 pg/ml, p = 0.002). BAFF decreased 36 ± 11.1 pg/mL for every 1 ng/mL increase in total testosterone (p = 0.002). This model explained 41% of the variation in circulating BAFF levels (model p < 0.0001). Our findings suggest that modifiable health habits may be associated with elevated BAFF levels in men with non-ambulatory chronic SCI. Further, the significant and independent negative association between testosterone levels and BAFF would suggest a link between androgen deficiency and autoimmunity observed in SCI via modulation of BAFF and B cell numbers. This points toward BAFF as a potential biomarker of injury severity and a target of therapies designed to reduce neuroinflammation and improve neurological outcomes after SCI.

Entities:  

Keywords:  B cell–activating factor (BAFF); biomarker; rehabilitation medicine; spinal cord injury; testosterone

Mesh:

Substances:

Year:  2019        PMID: 31020912      PMCID: PMC6892431          DOI: 10.1089/neu.2018.6221

Source DB:  PubMed          Journal:  J Neurotrauma        ISSN: 0897-7151            Impact factor:   5.269


  32 in total

1.  Association between sclerostin and bone density in chronic spinal cord injury.

Authors:  Leslie R Morse; Supreetha Sudhakar; Valery Danilack; Carlos Tun; Antonio Lazzari; David R Gagnon; Eric Garshick; Ricardo A Battaglino
Journal:  J Bone Miner Res       Date:  2012-02       Impact factor: 6.741

2.  Association between 25(OH)-vitamin D and testosterone levels: Evidence from men with chronic spinal cord injury.

Authors:  Arcangelo Barbonetti; Maria Rosaria C Vassallo; Giorgio Felzani; Sandro Francavilla; Felice Francavilla
Journal:  J Spinal Cord Med       Date:  2015-08-27       Impact factor: 1.985

Review 3.  B-cell-targeted treatment for multiple sclerosis: mechanism of action and clinical data.

Authors:  Kathleen Hawker
Journal:  Curr Opin Neurol       Date:  2008-04       Impact factor: 5.710

4.  Autoreactivity against myelin basic protein in patients with chronic paraplegia.

Authors:  D Zajarías-Fainsod; J Carrillo-Ruiz; H Mestre; I Grijalva; I Madrazo; A Ibarra
Journal:  Eur Spine J       Date:  2011-11-08       Impact factor: 3.134

5.  Lower Vitamin D Levels Are Associated With Depression in People With Chronic Spinal Cord Injury.

Authors:  Arcangelo Barbonetti; Francesca Cavallo; Settimio D'Andrea; Mario Muselli; Giorgio Felzani; Sandro Francavilla; Felice Francavilla
Journal:  Arch Phys Med Rehabil       Date:  2016-12-14       Impact factor: 3.966

6.  Prevalence of testosterone deficiency after spinal cord injury.

Authors:  Anita Durga; Farhad Sepahpanah; Mary Regozzi; James Hastings; Deborah A Crane
Journal:  PM R       Date:  2011-10       Impact factor: 2.298

7.  Clinical correlates of elevated serum concentrations of cytokines and autoantibodies in patients with spinal cord injury.

Authors:  Andrew L Davies; Keith C Hayes; Gregory A Dekaban
Journal:  Arch Phys Med Rehabil       Date:  2007-11       Impact factor: 3.966

8.  Improved regeneration after spinal cord injury in mice lacking functional T- and B-lymphocytes.

Authors:  Bin Wu; Dragana Matic; Nevena Djogo; Emanuela Szpotowicz; Melitta Schachner; Igor Jakovcevski
Journal:  Exp Neurol       Date:  2012-07-31       Impact factor: 5.330

9.  B-cell maturation antigen, a proliferation-inducing ligand, and B-cell activating factor are candidate mediators of spinal cord injury-induced autoimmunity.

Authors:  Jonah W Saltzman; Ricardo A Battaglino; Loise Salles; Prateek Jha; Supreetha Sudhakar; Eric Garshick; Helen L Stott; Ross Zafonte; Leslie R Morse
Journal:  J Neurotrauma       Date:  2013-03-28       Impact factor: 5.269

10.  B-cell-activating factor is a regulator of adipokines and a possible mediator between adipocytes and macrophages.

Authors:  Mi-Young Kim; Do-Hwan Kim; Myoung-Sool Do
Journal:  Exp Mol Med       Date:  2013-01-10       Impact factor: 8.718

View more
  2 in total

1.  Metformin prevents BAFF activation of Erk1/2 from B-cell proliferation and survival by impeding mTOR-PTEN/Akt signaling pathway.

Authors:  Xiaoling Chen; Jing Ma; Yajie Yao; Jiawei Zhu; Zhihan Zhou; Rui Zhao; Xiaoqing Dong; Wei Gao; Shuangquan Zhang; Shile Huang; Long Chen
Journal:  Int Immunopharmacol       Date:  2021-05-15       Impact factor: 5.714

2.  Smoking associates with increased BAFF and decreased interferon-γ levels in patients with systemic lupus erythematosus.

Authors:  Warren David Raymond; Matthew Hamdorf; Michael Furfaro; Gro Ostli Eilertsen; Johannes Cornelis Nossent
Journal:  Lupus Sci Med       Date:  2021-10
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.